At The Gene Sherpa, Steve Murphy points to a recent perspective in the New England Journal of Medicine that gives direct-to-consumer personal genome services a no-go. Contributing to the lack of enthusiasm for companies like 23andMe and Navigenics is the fear that they offer more uncertainty than anything else when put into the hands of physicians.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.